TG Therapeutics Announces European Commission Approval For BRIUMVI For The Treatment Of Relapsing Forms Of Multiple Sclerosis In Adults
Portfolio Pulse from Benzinga Newsdesk
TG Therapeutics announced that the European Commission has approved BRIUMVI for the treatment of relapsing forms of multiple sclerosis in adults. This approval will allow the company to market the drug in the European Union.
June 01, 2023 | 1:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TG Therapeutics received European Commission approval for BRIUMVI, allowing the company to market the drug for relapsing forms of multiple sclerosis in the EU.
The European Commission approval for BRIUMVI is a significant milestone for TG Therapeutics, as it allows the company to market the drug in the European Union. This will likely lead to increased revenues and a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100